On October 31, 2025 Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, reported the signing of a License Agreement with Japan-based RIN Institute Inc., granting Mycenax rights to apply RIN’s proprietary Val-Leu-Lys (VLK) linker technology in CDMO services worldwide.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
RIN’s VLK linker has demonstrated superior anti-tumor efficacy and high serum stability, enabling the development of advanced ADCs. Specifically, the VLK linker facilitates cytotoxicity through two mechanisms: action within the tumor microenvironment and enhanced ADC internalization. The agreement strengthens Mycenax’s capability to deliver differentiated ADC solutions for global pharmaceutical partners.
"We are thrilled to finalize this agreement with RIN Institute, marking an important milestone in our mission to provide innovative and competitive ADC solutions," said Pei-Jiun Chen, CEO and President of Mycenax. "This collaboration further enhances our technical capabilities and reinforces our commitment to advancing next-generation ADC therapeutics."
The partnership builds upon the Letter of Intent (LOI) signed on April 7, 2025, which laid the foundation for closer cooperation between the two companies in advancing ADC innovation.
(Press release, Mycenax, OCT 31, 2025, View Source [SID1234659213])